A Phase Ib, Open‐Label Study of Dalantercept, an Activin Receptor‐Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma

LESSONS LEARNED. Patients with hepatocellular carcinoma (HCC) often have limited therapeutic responses to the vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor sorafenib, which is standard of care in advanced HCC. Targeting the activin receptor‐like kinase 1 (ALK1) and VEGF pathway...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Abou‐Alfa, Ghassan K., Miksad, Rebecca A., Tejani, Mohamedtaki A., Williamson, Stephen, Gutierrez, Martin E., Olowokure, Olugbenga O., Sharma, Manish R., El Dika, Imane, Sherman, Matthew L., Pandya, Shuchi S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons, Inc. 2018
Soggetti:
Clinical Trial Results
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6369956/
https://ncbi.nlm.nih.gov/pubmed/30352941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0654
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi